Also trades as: NRXPW (NASDAQ) · $vol 0M
NRXP NASDAQ
NRx Pharmaceuticals, Inc.
1W: +5.6%
1M: -5.3%
3M: +70.2%
YTD: +15.7%
1Y: +23.7%
3Y: -51.9%
5Y: -98.9%
$2.96
-0.07 (-2.15%)
Weekly Expected Move ±15.5%
$2
$3
$3
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$52.4M
52W Range1.62-3.84
Volume467,316
Avg Volume947,683
Beta2.02
Dividend—
Analyst Ratings
Company Info
CEOJonathan C. Javitt
Employees2
SectorHealthcare
IndustryBiotechnology
IPO Date2017-12-04
Websitenrxpharma.com
1201 Orange Street
Wilmington, DE 19801
US
Wilmington, DE 19801
US
484 254 6134
About NRx Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Latest News
My Top 3 Biotech Stocks for May 2026
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
Here are the major earnings before the open Monday
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Casper Joseph Michae | A-Award | 100,000 | $2.39 | 2026-01-27 |
| Casper Joseph Michae | 100,000 | $2.39 | 2026-01-27 | |
| B Group, Inc. | 0 | — | 2025-08-18 | |
| Javitt Jonathan C | A-Award | 125,000 | $1.73 | 2025-04-09 |
| McBride Dennis | A-Award | 25,000 | $1.73 | 2025-04-09 |